Global Device Manufacturing Map: 24,795 FDA-Registered Establishments

Executive Summary

Every medical device sold in the United States must come from an establishment registered with the FDA. The FDA device establishment registration and listing database is therefore a comprehensive map of global medical device manufacturing capacity — and it tells a striking story about how international the supply chain has become.

Our analysis of the complete FDA device establishment registration and listing dataset — 417,036 establishment-product listing records covering 24,795 unique registered establishments across 100+ countries — reveals that 59.7% of all registered establishments are located outside the United States. China alone accounts for 4,753 establishments (19.2% of the global total), more than any other country including the US among foreign-only counts.

The data also show a sharp divergence in establishment roles: US establishments are heavily weighted toward specification development and repack/relabeling activities, while foreign establishments — particularly in China — are predominantly manufacturers, either producing their own brands or acting as contract manufacturers for others.

This article quantifies the global manufacturing footprint, identifies which countries dominate which product areas, and traces the growth trends reshaping the device supply chain.

Data Source and Methodology

All statistics in this article are derived from our direct analysis of the FDA device establishment registration and listing database (public dataset, extracted June 2026). The dataset covers all active registered establishments and their listed products. Each record represents an establishment-product pair (one establishment listing one product code). The 417,036 listing records map to 24,795 unique establishments identified by FEI number.

Establishment types were simplified into categories: own-brand manufacturer, contract manufacturer, contract sterilizer, specification developer, repack/relabeler, exporter only, and other. Facilities performing multiple roles were classified by their primary activity. Country codes were mapped to standard ISO country names.

The Big Picture: 40% US, 60% Foreign

Of the 24,795 unique registered establishments, the US-foreign split is:

This means nearly three in five FDA-registered device establishments are located outside the United States. Foreign establishments are not marginal participants — they are the majority of the registered device supply chain.

Top 25 Countries by Registered Establishments

The top 10 countries account for 84.2% of all establishments. The top 5 foreign countries (China, Germany, South Korea, Canada, Taiwan) represent 49.3% of all foreign establishments — meaning just five countries account for nearly half of the non-US manufacturing base.

China's dominance is structural. With 4,753 establishments, China has nearly 4.5 times the next foreign country (Germany, 1,071). China alone holds 32.1% of all foreign establishments — nearly one in three foreign FDA-registered facilities is Chinese.

Establishment Type: Who Does What

Registered establishments declare one or more activities. After simplifying the primary role for each facility:

Roughly half of all establishments manufacture devices under their own brand. Nearly one-quarter are contract manufacturers — producing devices for other companies under the hiring firm's specifications. The 5.6% classified as "exporter only" are foreign establishments whose sole FDA-registered activity is exporting devices to the US without further processing.

Manufacturing Role by Country: A Stark Divergence

The mix of establishment types varies dramatically between the US and top foreign countries:

United States (9,992 establishments)

The US stands out for its high share of specification developers (22.1%) and repack/relabelers (14.2%). Many US establishments design devices but outsource the physical manufacturing to foreign contract facilities.

China (4,753 establishments)

China's profile is heavily weighted toward manufacturing — 91.8% of Chinese establishments are either own-brand manufacturers or contract manufacturers. The near-absence of specification developers (0.7%) and repack/relabelers reinforces that China's role in the supply chain is overwhelmingly as a production hub.

South Korea (840 establishments)

South Korea has the highest own-brand manufacturing share among major countries at 82.3%. Korean establishments are primarily domestic manufacturers selling their own branded devices into the US market, with minimal contract manufacturing activity.

Germany (1,071 establishments)

Germany's mix resembles a more balanced version of China's — strong in both own-brand and contract manufacturing, with a meaningful specification development presence.

Product Areas by Country: What Each Nation Produces

The top product codes listed at establishments vary significantly by country, reflecting each nation's manufacturing specialization.

China: Diversified Diagnostic and Hospital Devices

China has 2,540 distinct product codes across its 4,753 establishments. The top-listed product codes are dominated by consumer health devices, surgical supplies, and diagnostic instruments:

China's product mix spans consumer health wearables, patient monitoring, ultrasound diagnostics, surgical supplies, and physical medicine devices. The breadth of 2,540 product codes means Chinese manufacturing is not concentrated in a single niche.

Germany: Surgical Instruments and Orthopedics

Germany lists 2,434 distinct product codes. Its top codes reflect strength in surgical instruments and orthopedic implants:

South Korea: Dental and Ultrasound Imaging

South Korea's 970 product codes are concentrated in ultrasound imaging and dental implants:

Japan: Ultrasound and CT Imaging

Japan's 1,060 product codes are led by ultrasound and CT imaging systems:

Japan's heavy concentration in ITX/IYO/IYN product families (ultrasound diagnostic and imaging systems) aligns with the country's strength in medical imaging technology from manufacturers like Canon Medical, Fujifilm, and Hitachi.

Growth Trends: China's Acceleration

Listing volume by year shows the trajectory of each country's FDA engagement:

China's listings spiked dramatically in 2020 (4,671, nearly double the prior year) — driven by the COVID-era surge in PPE and diagnostic device registrations. After normalizing in 2021–2022, listing volume resumed growth, reaching 5,156 in 2024. The 2020 spike is visible but the underlying trend is upward even excluding that anomaly.

US listing volume has also grown substantially, from 9,736 in 2018 to 15,233 in 2025 — a 56.5% increase. This reflects both organic growth and the expansion of specification development and contract manufacturing relationships within the US.

US Geographic Distribution

Among the 9,992 US establishments, California leads by a wide margin:

California's dominant position (29,255 listings) reflects the concentration of medical device specification developers, manufacturers, and digital health companies in the state. The presence of Indiana, Massachusetts, and Minnesota in the top tier reflects the legacy headquarters of major device companies (Baxter/Abbott in Illinois, Boston Scientific in Massachusetts, Medtronic in Minnesota).

What This Means for Industry

Three implications emerge:

1. The supply chain is global, and increasingly so. With 59.7% of establishments foreign, any discussion of US device supply chain resilience must account for the dependence on facilities in China, Germany, South Korea, and other countries. Nearshoring and reshoring initiatives are competing against a deeply established foreign manufacturing base.

2. China is both manufacturer and brand owner. With 60.9% of Chinese establishments operating as own-brand manufacturers, China is not just a contract manufacturing hub — it is developing and selling its own devices directly into the US market. The remaining 30.9% contract manufacturing share means Chinese facilities are also producing for Western brand owners.

3. The US role has shifted toward design and specification. The 22.1% specification developer share among US establishments, combined with 14.2% repack/relabeling, suggests that many US companies design devices domestically and manufacture them abroad. This "design here, build there" model has supply chain implications for regulatory oversight, quality control, and import compliance.

Data source: FDA device establishment registration and listing database; analysis by MedDeviceGuide, run date 2026-06-10. Analysis sample: complete active registration and listing extract, 417,036 establishment-product records representing 24,795 unique establishments.